1. Home
  2. Analysis
  3. Dulcolax
  4. Enzalutamide

Dulcolax and Enzalutamide drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Dulcolax (bisacodyl) and Enzalutamide (enzalutamide). Common drug interactions include cardiac failure congestive among males.

The phase IV clinical study analyzes what interactions people have when they take Dulcolax and Enzalutamide. It is created by eHealthMe based on reports of 25 people who take the same drugs from the FDA, and is updated regularly.

What is Dulcolax?

Dulcolax has active ingredients of bisacodyl. It is often used in constipation. eHealthMe is studying from 12,897 Dulcolax users. Check the latest studies of Dulcolax.

What is Enzalutamide?

Enzalutamide has active ingredients of enzalutamide. eHealthMe is studying from 14,018 Enzalutamide users. Check the latest studies of Enzalutamide.

On Jul, 15, 2026

25 people who take Dulcolax and Enzalutamide together, and have interactions are studied.

Dulcolax and Enzalutamide drug interactions.

What are the common drug interactions of Dulcolax and Enzalutamide, by gender? *:

female:

n/a

male:

  1. Cardiac failure congestive
  2. Gastric disorder (disease of stomach)
  3. Syncope (loss of consciousness with an inability to maintain postural tone)
  4. Ageusia (loss of taste functions of the tongue)
  5. Amnesia (deficit in memory caused by brain damage, disease, or psychological trauma)
  6. Anaemia (lack of blood)
  7. Anxiety
  8. Arthralgia (joint pain)
  9. Back pain
  10. Blood pressure fluctuation

What are the common drug interactions of Dulcolax and Enzalutamide, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

  1. Asthenia (weakness)
  2. Cardiac failure congestive
  3. Syncope (loss of consciousness with an inability to maintain postural tone)
  4. Ageusia (loss of taste functions of the tongue)
  5. Amnesia (deficit in memory caused by brain damage, disease, or psychological trauma)
  6. Anaemia (lack of blood)
  7. Anxiety
  8. Arthralgia (joint pain)
  9. Back pain
  10. Blood pressure fluctuation

What are the existing conditions these people have? *

  1. Prostate Cancer: 17 people, 68.00%
  2. Prostate Cancer Metastatic: 6 people, 24.00%
  3. High Blood Pressure: 5 people, 20.00%
  4. Joint Pain: 4 people, 16.00%
  5. Hyperlipidaemia (presence of excess lipids in the blood): 4 people, 16.00%
  6. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 4 people, 16.00%
  7. Pain: 3 people, 12.00%
  8. Pollakiuria (abnormally frequent passage of relatively small quantities or urine): 2 people, 8.00%
  9. Metastasis (spreadable cancer to other organ from origin): 2 people, 8.00%
  10. Hypotension (abnormally low blood pressure): 2 people, 8.00%

* Approximation only. Some reports may have incomplete information.

Do you take Dulcolax and Enzalutamide?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Dulcolax and Enzalutamide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Dulcolax:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Enzalutamide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Dulcolax and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Enzalutamide and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on bisacodyl and enzalutamide (the active ingredients of Dulcolax and Enzalutamide, respectively), and Dulcolax and Enzalutamide (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.